Richard Ian Griffiths, a director and 10% owner of Silence Therapeutics plc (NASDAQ:SLN), filed a Form 4 on August 13, 2026, disclosing multiple disposals of American Depositary Shares in Silence Therapeutics on August 10, 2026.

Key Highlights

  • Reporting person: Richard Ian Griffiths, listed as both a director and 10% owner of Silence Therapeutics plc.
  • Security type: American Depositary Shares (ADS), each immediately convertible into three ordinary shares for no consideration and with no expiration date.
  • Transaction date: All sales were executed on August 10, 2026, across eleven separate reported transactions.
  • Sale prices: Transactions were executed at prices of $16.00, $15.58, $16.09, and $16.35 per ADS, according to the filing.
  • Aggregate ADS sold: Totaling across all reported lines, disposals included 2,792,826, 100,000, 50,000, 3,500, 800,000, 382,000, 470,820, 605,174, 120,000, 60,000, and 100,000 ADS in separate transactions.
  • Remaining beneficial ownership: Following all reported transactions, the filing states 4,797,166 ordinary shares beneficially owned indirectly.
  • Selling entities: Sales were made by Cream Capital Limited, Blake Holdings Limited, Ora Ventures Limited, Ora Capital Limited, Sarossa Plc, Pinkeys Limited, and Mr. Griffiths personally, according to the filing.

Director ADS Disposals Across Multiple Entities at Silence Therapeutics

According to the filing, Griffiths reported eleven separate disposal transactions in Silence Therapeutics ADS, all dated August 10, 2026. The transactions were coded "S" (sale) and carried out at four distinct prices: $16.00, $15.58, $16.09, and $16.35 per ADS. Silence Therapeutics is a clinical-stage biopharmaceutical company focused on RNA interference therapeutics. Each ADS is described in the filing as immediately convertible into three ordinary shares for no consideration and with no expiration date.

The filing notes that the securities were sold by multiple entities over which Griffiths holds control, including Cream Capital Limited, Blake Holdings Limited, Ora Ventures Limited, Ora Capital Limited, Sarossa Plc, and Pinkeys Limited, as well as by Griffiths personally. The filing further states: "Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein." All transactions are reported as indirect ownership. After the final reported transaction, the filing records indirectly held beneficial ownership of 4,797,166 ordinary shares.

The Form 4 was signed by Richard Ian Griffiths and filed on August 13, 2026, covering transactions with an earliest transaction date of August 10, 2026. The filing was submitted as an individual filing by one reporting person.

What Was Disclosed

Griffiths disclosed eleven ADS disposal transactions in Silence Therapeutics on August 10, 2026, conducted through multiple controlled entities and personally, at prices ranging from $15.58 to $16.35 per ADS, with remaining indirect beneficial ownership of 4,797,166 ordinary shares following all transactions.